Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)
CPD Review
Keywords: castration-resistant prostate cancer, prostate-specific antigen, docetaxel, cytotoxic agents, first-line therapy, second-line therapy
Authors: Daniel J. Lee, Eugene K. Cha, Justin M. Dubin, Himisha Beltran, Thomas F. Chromecki, Harun Fajkovic, Douglas S. Scherr, Scott T. Tagawa, Shahrokh F. Shariat
Learning Objectives
After reading this paper you will be able to:
- Summarise the advantages and disadvantages of biomarkers in the management of CRPC
- Describe the evidence for new therapeutic combinations with docetaxel and new cytotoxic agents in the treatment of CRPC
- Identify novel therapeutic targets and summarise the evidence for their use in the treatment of CRPC
- Summarise the evidence supporting the role of bisphosphonates and radionuclides in the treatment of bone metastases in men with CRPC